AstraZeneca Q3 2026 Earnings - Core EPS: $2.79 (est $2.62) - Revenue: $16.21B (est $15.98B) - Core Operating Margin: 36% (est 33.6%) - Imfinzi Revenue: $1.99B (est $1.96B) - Farxiga Revenue: $1.61B - Reconfirms Revenue And Core EPS Guidance 30-OCT-2026 05:21 AM ET